Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
about
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective StudyEfficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
P2860
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
@en
type
label
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
@en
prefLabel
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
@en
P2860
P1476
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
@en
P2093
Ian Judson
Juan Martin-Liberal
P2860
P304
P356
10.1517/14740338.2013.829037
P407
P577
2013-08-12T00:00:00Z